Protein corona–mediated targeting of nanocarriers to B cells allows redirection of allergic immune responses

[1]  S. Durham,et al.  Novel approaches and perspectives in allergen immunotherapy , 2017, Allergy.

[2]  John D Lambris,et al.  Complement component C3 – The “Swiss Army Knife” of innate immunity and host defense , 2016, Immunological reviews.

[3]  P. Reche,et al.  Novel vaccines targeting dendritic cells by coupling allergoids to nonoxidized mannan enhance allergen uptake and induce functional regulatory T cells through programmed death ligand 1. , 2016, The Journal of allergy and clinical immunology.

[4]  M. Jutel,et al.  Allergen Immunotherapy: Past, Present, and Future , 2015, Allergy, asthma & immunology research.

[5]  A. Boldt,et al.  MBL-associated serine proteases (MASPs) and infectious diseases , 2015, Molecular Immunology.

[6]  Stefan Tenzer,et al.  Protein corona of nanoparticles: distinct proteins regulate the cellular uptake. , 2015, Biomacromolecules.

[7]  T. Fahmy,et al.  Investigation of peanut oral immunotherapy with CpG/peanut nanoparticles in a murine model of peanut allergy. , 2015, The Journal of allergy and clinical immunology.

[8]  H. Schild,et al.  IL-10 and Regulatory T Cells Cooperate in Allergen-Specific Immunotherapy To Ameliorate Allergic Asthma , 2015, The Journal of Immunology.

[9]  C. Berkland,et al.  Multivalent nanomaterials: learning from vaccines and progressing to antigen-specific immunotherapies. , 2015, Journal of pharmaceutical sciences.

[10]  Stefan Tenzer,et al.  Biomedical applications of ion mobility-enhanced data-independent acquisition-based label-free quantitative proteomics , 2014, Expert review of proteomics.

[11]  J. Irache,et al.  Nanoparticle based-immunotherapy against allergy. , 2014, Immunotherapy.

[12]  Stefan Tenzer,et al.  Quantitative profiling of the protein coronas that form around nanoparticles , 2014, Nature Protocols.

[13]  K. Gibson-Corley,et al.  Development of a Poly (lactic-co-glycolic acid) Particle Vaccine to Protect Against House Dust Mite Induced Allergy , 2014, The AAPS Journal.

[14]  M. Carroll,et al.  Follicular dendritic cells: dynamic antigen libraries , 2014, Nature Reviews Immunology.

[15]  L. Delamarre,et al.  Dendritic Cell-Targeted Vaccines , 2014, Front. Immunol..

[16]  C. Akdis,et al.  Mechanisms of allergen-specific immunotherapy: multiple suppressor factors at work in immune tolerance to allergens. , 2014, The Journal of allergy and clinical immunology.

[17]  D. Klinman,et al.  Recent progress concerning CpG DNA and its use as a vaccine adjuvant , 2014, Expert review of vaccines.

[18]  H. Schild,et al.  A Trifunctional Dextran-Based Nanovaccine Targets and Activates Murine Dendritic Cells, and Induces Potent Cellular and Humoral Immune Responses In Vivo , 2013, PloS one.

[19]  R. Pike,et al.  The molecular switches controlling the interaction between complement proteases of the classical and lectin pathways and their substrates. , 2013, Current opinion in structural biology.

[20]  Stefan Tenzer,et al.  Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. , 2013, Nature nanotechnology.

[21]  R. O’Donnell,et al.  Targeting CD22 in B-cell Malignancies: Current Status and Clinical Outlook , 2013, BioDrugs.

[22]  N. Daver,et al.  Novel Therapeutic Strategies in Adult Acute Lymphoblastic Leukemia – A Focus on Emerging Monoclonal Antibodies , 2013, Current Hematologic Malignancy Reports.

[23]  Andrzej S Pitek,et al.  Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. , 2013, Nature nanotechnology.

[24]  P. Hari,et al.  Characteristics of CliniMACS® System CD34-enriched T cell-depleted grafts in a multicenter trial for acute myeloid leukemia-Blood and Marrow Transplant Clinical Trials Network (BMT CTN) protocol 0303. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[25]  J. Banchereau,et al.  Targeting self- and foreign antigens to dendritic cells via DC-ASGPR generates IL-10–producing suppressive CD4+ T cells , 2012, The Journal of experimental medicine.

[26]  John Steel,et al.  Programming the magnitude and persistence of antibody responses with innate immunity , 2010, Nature.

[27]  B. Goldman,et al.  The cancer vaccine roller coaster , 2009, Nature Biotechnology.

[28]  I. Bakunina,et al.  Structure, biological activity, and enzymatic transformation of fucoidans from the brown seaweeds , 2008, Biotechnology journal.

[29]  N. Kaminski,et al.  Modulation of Airway Responses to Influenza A/PR/8/34 by Δ9-Tetrahydrocannabinol in C57BL/6 Mice , 2007, Journal of Pharmacology and Experimental Therapeutics.

[30]  R. Coffman,et al.  Immunotherapy With a Ragweed-Toll-Like Receptor 9 Agonist Vaccine for Allergic Rhinitis , 2007, Pediatrics.

[31]  S. Akira,et al.  Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus , 2005, The Journal of experimental medicine.

[32]  Q. Hamid,et al.  Advances in mechanisms of allergy. , 2004, The Journal of allergy and clinical immunology.

[33]  D. Busch,et al.  CpG-DNA Aided Cross-Priming by Cross-Presenting B Cells1 , 2004, The Journal of Immunology.

[34]  S. Thiel,et al.  Lack of mannose-binding lectin-A enhances survival in a mouse model of acute septic peritonitis. , 2002, Microbes and infection.

[35]  W. Heath,et al.  Defective TCR expression in transgenic mice constructed using cDNA‐based α‐ and β‐chain genes under the control of heterologous regulatory elements , 1998, Immunology and cell biology.

[36]  E. Kremmer,et al.  Regulation of the B cell response to T-dependent antigens by classical pathway complement. , 1996, Journal of immunology.

[37]  R. Karr,et al.  Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[38]  P. Butko,et al.  Studies of group B streptococcal infection in mice deficient in complement component C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[39]  J. West,et al.  B lymphocytes can be competent antigen-presenting cells for priming CD4+ T cells to protein antigens in vivo. , 1995, Journal of immunology.

[40]  B. Heyman,et al.  Antibodies to murine complement receptor 1 and 2 can inhibit the antibody response in vivo without inhibiting T helper cell induction. , 1995, Journal of immunology.

[41]  R. Soltis,et al.  Studies on the nature of heat-labile anti-complementary activity in normal human serum. , 1979, Clinical and experimental immunology.

[42]  A. M. Prantner,et al.  Biological barriers and current strategies for modifying nanoparticle bioavailability. , 2014, Journal of nanoscience and nanotechnology.

[43]  Andreas Radbruch,et al.  High gradient magnetic cell separation with MACS. , 1990, Cytometry.